Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC weight-loss guidance

This article was originally published in The Tan Sheet

Executive Summary

Commission will accept comments on recent workshop, eight identified weight-loss ad claims through Feb. 3. During Strategic Research Institute conference Dec. 9, Division of Advertising Practices Senior Staff Attorney Richard Cleland noted that after comment period closes, FTC will put together staff report with recommendations on whether eight claims are scientifically feasible, as well as suggestions on industry self-regulation, media screening of weight-loss ads. November workshop featured scientific panel that almost unanimously concluded eight weight-loss claims, such as "works for everyone," lack sufficient scientific support (1"The Tan Sheet" Nov. 25, 2002, p. 4)...

You may also be interested in...



“Substantial” Weight-Loss Ad Claims Not Scientifically Verifiable – FTC Panel

Weight loss greater than one pound per week is not scientifically feasible with OTC drugs and dietary supplements, a panel of scientific and medical experts asserted

Can Organovo Leverage Its Solid Phase II Data In MASH?

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094902

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel